Find Your Broker
Share Name Share Symbol Market Type Share ISIN Share Description
Evgen Pharma LSE:EVG London Ordinary Share GB00BSVYN304 ORD 0.25P
  Price Change % Change Share Price Shares Traded Last Trade
  +0.50p +3.08% 16.75p 90,471 08:25:51
Bid Price Offer Price High Price Low Price Open Price
16.00p 17.50p 16.75p 16.25p 16.25p
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology -3.03 -3.28 16.6

Evgen Pharma (EVG) Latest News

More Evgen Pharma News
Evgen Pharma Takeover Rumours

Evgen Pharma (EVG) Share Charts

1 Year Evgen Pharma Chart

1 Year Evgen Pharma Chart

1 Month Evgen Pharma Chart

1 Month Evgen Pharma Chart

Intraday Evgen Pharma Chart

Intraday Evgen Pharma Chart

Evgen Pharma (EVG) Discussions and Chat

Evgen Pharma (EVG) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
2018-12-11 15:00:5016.1020.32O
2018-12-11 14:51:4616.9011,8341,999.95O
2018-12-11 13:02:3716.102,252362.57O
2018-12-11 10:34:3616.1015,0002,415.00O
2018-12-11 09:52:1616.0036,3835,821.28O
View all Evgen Pharma trades in real-time

Evgen Pharma (EVG) Top Chat Posts

DateSubject
11/12/2018
08:20
Evgen Pharma Daily Update: Evgen Pharma is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker EVG. The last closing price for Evgen Pharma was 16.25p.
Evgen Pharma has a 4 week average price of 16.25p and a 12 week average price of 13p.
The 1 year high share price is 27.80p while the 1 year low share price is currently 12p.
There are currently 98,912,416 shares in issue and the average daily traded volume is 86,869 shares. The market capitalisation of Evgen Pharma is £16,567,829.68.
13/11/2018
10:52
aoifesweb: This is my favourite bit ‘Analysts at Northland Capital currently have a price target of 113p on the shares, providing over 500% upside from today’s share price. The global market opportunity in metastatic breast cancer alone for SFX-01 is estimated to be between US$6 to US$7bn/year, with this in mind it’s easy to see why analysts expect the shares perform so well.‘: Https://uk-investor.com/2018/11/12/could-evgen-pharma-lonevg-make-you-a-millionaire-in-2019/
19/9/2018
16:25
francisgalton: It's the same broker, Vadim, who pumped Immupharma before their share price collapsed after mixed trial results. Not anyone whose word should be hung onto.
18/9/2018
11:27
pdt: I see the slide sets are now online on the Evgen website. Lots of information. Good to see confirmation that we should get pre-clinical data on Stroke, Autism and Triple Negative Breast Cancer in Q4. The news on TNBC looks like it will be positive since the slide set about STEM indicated that SFX-01 worked in a similar way with TNBC. Also in the patient 1 case study it looks like another person's disease has been stabilised for at least 16 months from May 17 to Sept 18 (latest scan). All looks very positive to me but perhaps that will not be reflected in the share price until we have a positive phase II result ??
13/6/2018
11:25
teddy boy1: Have just checked on todays trading and see that BUYS outweigh sells by half as much again and yet the share price is way down on the day.! How can this be right (morally) Can someone please explain the logic behind all this ?( apart from share price manipulation of the first degree)
13/6/2018
11:14
teddy boy1: There should be a law against what has happened this morning ;the way the share price was systematically taken down to encourage more sales.This share is definitely being "worked " and the bottom line is that all the shorters and the market makers have made themselves a shed load of money over the past 3 days- and this is on a GOOD trial update ! Think of what would have happened if the news had been bad! On second thoughts the share price would not have been too much different ,left to its own devices. Anyhow this is AIM , and this is how things are ! Perhaps companys such as EVGEN and IDP with very tightly held shares should be avoided like the plague as they are prime candidates for manipulation . With such companys;until they have proved themselves 100 per cent, the seeds of doubt will be sown and before we know where we are the share price has been worked down until the share price bears no resemblance to its true value. This is a real pity as I have not read anything myself which would encourage me to dispose of my shares as, as far as I am concerned ,Evgen Pharma has a very bright future .However ,it could still be many months/years before we are allowed a TRUE share price which values the company for what it is worth and not what some individuals CAUSE it to be, in the quest to make some easy money for themselves, over and over again! Anyone else agree with my sentiments?
12/6/2018
15:14
teddy boy1: The fact that the share price jumped up by 8 per cent as soon as the trial update was announced says it all as far as I am concerned. ! It was then decided that the share price HAD to come down by the market makers (and probably some shorters as well!) and this is what has been happening but as soon as they feel that they have taken it as low as it will go ,expect to see a big reversal! You heard it here first!
12/6/2018
10:48
teddy boy1: Still a decent amount of buying going on so it seems that there are many who have "kept the faith", which in the light of the trial update is not too surprising. It is clear to me that the share price was stepped down yesterday by the market makers in order to try and sow doubt so that they could accumulate some more of these tightly held shares. Within the next day or two the process will be reversed. The share price will be stepped up at the beginning of the day and this will attract buyers. How do I know.?- because this process is being repeated again and again on shares such as this.! The bottom line is that the update reads very well and gives encouragement to the company to plough ahead to demonstrate to all concerned that they have a winner on their hands.This is ,of course , assuming that they do not get taken out before very long by one of the big pharmas who will be able to see that this treatment definitely "has legs" and consequently could, in time, be a useful and profitable addition to their portfolio WATCH THIS SPACE!
11/6/2018
18:57
teddy boy1: It is pleasing to see that Northland Capital having seen the trial update,are still of the opinion that the share price target should remain unchanged at 113P. In my opinion there has been a certain amount of share price manipulation to-day as there has been more buying than selling. If past experience is anything to go by, I will be very surprised if the price does not show a nice "correction" tomorrow. Things are still on course for Evgen although it will be another 6 months before this has been one hundred per cent proved. In the meantime I am still more that happy to have this share in my portfolio!
04/6/2018
13:35
teddy boy1: A penny a day increase in the share price does not seem too ambitious to me. !The potential is enormous. I can see the share price ending the day quite a bit higher that it currently stands!
03/5/2018
14:04
bernymadoff: Only idiots look at the rise and fall of a share price to determine whether they should invest and at what price. It wasn't long ago that institutions were paying 37p on IPO to get exposure to the drugs EVG are testing. Since then many of them have continued to buy and they currently hold 55% or so of the whole company. Institutional investment is one of the major ingredients I look for when deciding to invest anywhere. It gives you a level of confidence knowing that experts have evaluated the company to a degree that lay people could not achieve. Big plus there. Then there is the performance of the company. To date EVG have not put a foot wrong and all their drug trials have exceeded market expectations. Yet the market has not assigned any value to the progress the company has made since IPO in October 2015. Like many other pre-revenue AIM companies with great potential it has been at the mercy of the spivs in the city who have manipulated the share price down so that they can screw the company in the knowledge that it is dependent on placings to see it through to commercialisation. There is a wealth of information out there showing just how disconnected the share price is to the actual potential of EVG. For me that's where the opportunity lies. The greater the disconnect the greater the correction (in fact in these cases the correction often overshoots to the overvalued side). The other big thing the company has going for it is that it is funded through to the end of the year by which point it may well have landed a licensing or JV deal if the results due this quarter and then again at the end of the year are any good. Certainly the CEO has been dropping hints to that effect in recent rns'. You can choose to play the swings or you can hold for the big prize that the evidence suggests is now within grasp.
Evgen Pharma share price data is direct from the London Stock Exchange
Your Recent History
LSE
EVG
Evgen Phar..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20181212 06:07:34